# Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab

> **NCT05411887** · — · ACTIVE_NOT_RECRUITING · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 2845 (actual)

## Conditions studied

- Hyperlipidemias
- Hypertension

## Interventions

- **DRUG:** Rosuvastatin, Olmesartan Medoxomil

## Key facts

- **NCT ID:** NCT05411887
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-20
- **Primary completion:** 2025-03-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 2845 (ACTUAL)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05411887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05411887, "Study to Evaluate the Effect of Improving Systolic BP and LDL-C Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar Tab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05411887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*